Epithalon (Epitalon)
Anti-Aging / LongevityAlso known as: Epitalon, Epithalone, AEDG Peptide
Mechanism
A four-amino-acid peptide (Ala-Glu-Asp-Gly) developed by Russian gerontologist Vladimir Khavinson. It activates telomerase — the enzyme that rebuilds the protective caps on your chromosomes — potentially slowing cellular aging. In studies, it extended lifespan in animals and reactivated telomerase in aging human cells.
Technical detail
Synthetic tetrapeptide (AEDG) analog of epithalamin, a pineal gland extract. Activates telomerase (hTERT) in human somatic cells, elongating telomeres in cell culture (Khavinson & Bondarev, 2003). In rodent studies, extended mean lifespan by 13.3% (Khavinson et al., 2003). Also restores melatonin secretion in aging pineal gland, normalizes circadian cortisol rhythms, and modulates antioxidant enzyme expression (SOD, GPx). No Western clinical trials, but extensive Russian clinical data spanning 15+ years.
Effects
MUSCULOSKELETAL: Indirect benefits via telomerase activation — telomere shortening in satellite cells (muscle stem cells) limits regenerative capacity; telomerase reactivation may extend satellite cell replicative lifespan (in vitro). Improved sleep quality and GH secretion from pineal restoration supports muscle repair. CARDIOVASCULAR: Restores melatonin rhythm which is cardioprotective (antioxidant, endothelial support). In Khavinson's landmark 6-year human study, epithalon + thymalin reduced cardiovascular mortality by 4.1x in elderly patients (n=266, Khavinson & Morozov, 2003 — clinical trial, Russian registration). Antioxidant enzyme upregulation (SOD, catalase, GPx) protects vascular endothelium (animal). NEUROLOGICAL: Restores pineal melatonin secretion (animal: Khavinson et al., 2003 — reversed age-related melatonin decline in monkeys). Melatonin is neuroprotective, antioxidant, and supports neurogenesis. Improved circadian function supports cognitive performance and reduces neurodegeneration risk. ENDOCRINE: Primary endocrine target: activates telomerase (hTERT) in human somatic cells (in vitro: Khavinson & Bondarev, 2003). Restores pineal gland melatonin synthesis by normalizing AANAT and HIOMT enzyme expression. Normalizes circadian cortisol rhythm. Downstream: improved GH pulsatility through restored deep sleep architecture. In aged monkeys, restored melatonin peak to youthful levels and normalized cortisol (animal). IMMUNE: Telomerase activation extends T-cell replicative capacity — aging immune cells (immunosenescence) have shortened telomeres limiting clonal expansion. In Khavinson's human study, epithalon normalized T-cell subsets and improved immune function parameters in elderly subjects (Russian clinical data). Melatonin restoration enhances NK cell activity. METABOLIC: Upregulates antioxidant defense enzymes: superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx) (animal). Reduces lipid peroxidation markers. Improves glucose tolerance in aged animals (animal). Melatonin restoration normalizes circadian metabolic cycling. SKIN: Telomerase activation in fibroblasts could theoretically slow skin aging at the cellular level (in vitro). Melatonin is a skin antioxidant. GI: No direct GI effects documented. HEPATIC: Antioxidant enzyme upregulation may be hepatoprotective (animal). REPRODUCTIVE: Telomere length in oocytes and sperm is critical for fertility — telomerase activation could theoretically support reproductive longevity (speculative). LONGEVITY-SPECIFIC: Extended mean lifespan by 13.3% in rodents (Khavinson et al., 2003). Extended maximum lifespan in fruit flies by 11-16% (Khavinson et al., 2002). Reduced spontaneous tumor incidence in aged mice by 1.6-3.7x (animal). In the 6-year human study (n=266 elderly, ages 60-80): 2.2x reduction in mortality rate in treated group vs. controls (Khavinson, 2003). Tier 3: This is one of the most-used peptides in the anti-aging community. Practitioner observations consistently report improved sleep quality, energy, and skin appearance within 2-4 weeks of starting a course. Some practitioners monitor telomere length before and after (via blood test) and report modest but consistent lengthening after 2-3 courses over 12-18 months (case series, unpublished).
Practitioner Guide
DOSING TIPS: Two main protocols: (1) Injectable — 5-10mg subcutaneous injection daily for 10-20 days, repeated every 4-6 months. This is the most common practitioner protocol. (2) Oral — capsule form exists but bioavailability is debated for this tetrapeptide. Some practitioners prefer sublingual administration. Typical injectable protocol: 10mg subQ daily x 20 days, then off for 4-6 months. Some aggressive protocols use 10mg 2x/day for 10 days. Start conservative. RECONSTITUTION: Lyophilized powder — reconstitute with bacteriostatic water (BAC water). For 10mg vial: add 1mL BAC water = 10mg/mL. Draw 0.1mL (1mg) to 1mL (10mg) depending on dose. Use insulin syringe (29-31 gauge). Stable for 4-6 weeks refrigerated after reconstitution. INJECTION SITE: Subcutaneous — abdominal fat pad (rotate sites), thigh, or upper arm. Inject slowly. Minimal pain with insulin needles. Some practitioners use it intramuscularly for potentially faster absorption. TIMING: Evening injection preferred (aligns with pineal activation cycle and melatonin rhythm). 30-60 minutes before bed. On an empty stomach (no specific food interaction, but fasted state may improve peptide absorption). SUPPLEMENT SYNERGIES: Stack with Thymalin for the Khavinson anti-aging protocol (Epithalon for telomeres/pineal + Thymalin for thymus/immunity). Add Endoluten for the full "Khavinson triad." Ensure adequate zinc, selenium, and B-vitamins to support telomerase and melatonin pathways. Vitamin D3 — co-regulates telomerase expression. Astragaloside IV and cycloastragenol (from astragalus) also activate telomerase — some practitioners combine for synergistic telomere support. NAD+ precursors (NMN/NR) support sirtuin-telomere maintenance axis. CYCLING: Course-based protocol is essential — 10-20 day course, then 4-6 month break. This follows the Khavinson bioregulator paradigm of "cellular reprogramming" with lasting effects. Most practitioners recommend 2 courses per year. Do NOT use continuously. STACKING: Anti-aging stack: Epithalon + Thymalin + GHK-Cu + BPC-157. Longevity stack: Epithalon + NAD+ precursor + Endoluten + senolytics (FOXO4-DRI or fisetin). Sleep/recovery: Epithalon + DSIP + GHRP-6. CONTRAINDICATION NUANCES: Theoretical concern with active cancer — telomerase is upregulated in most cancers. However, Khavinson's animal data showed REDUCED tumor incidence. The consensus among informed practitioners is that physiological telomerase activation differs from pathological (cancer) telomerase. Still, most practitioners avoid in patients with active malignancy as a precaution. Screen patients over 40 with basic cancer markers before starting. Patients on anticoagulants — melatonin has mild antiplatelet effects. STORAGE: Lyophilized powder — room temperature or refrigerated, protect from light. Reconstituted — refrigerate, use within 4-6 weeks. Travel: transport lyophilized vials at room temp, reconstitute at destination. COMPOUNDING: Available from research peptide suppliers and some compounding pharmacies that carry research-grade peptides. Not FDA-regulated — quality varies. Advise patients to source from suppliers who provide third-party CoA (Certificate of Analysis) with HPLC purity >98%. PATIENT EDUCATION: This is the most studied of the Khavinson bioregulator peptides. Explain the course-based approach — it's not daily supplementation, it's periodic cellular "maintenance." Track sleep quality, energy levels, and optionally telomere length via blood test. Effects are cumulative over multiple courses. Many patients notice improved sleep within the first week. The anti-cancer data in animals is reassuring but explain the theoretical concern. Tier 4 community intelligence: The biohacking community widely uses epithalon, typically sourcing from research peptide vendors. Common reports: dramatically improved sleep quality (most consistent finding), improved skin texture, and enhanced dream recall. Some users report feeling "younger" in a general sense after 2-3 courses. Telomere testing (via TeloYears, SpectraCell, or Life Length) before and after is becoming standard in the community — typical report is 100-300 base pair increase after 1 year (2 courses). Skeptics note that Russian data has not been independently replicated in Western trials.
Dosing Protocols
- Dose
- 5000mcg
- Frequency
- Once daily for 10-20 consecutive days; repeat 1-2x per year
- Timing
- Evening, 1-2 hours before bed
- Route
- subcutaneous
- Cycle
- 2-3 weeks
Standard Khavinson protocol: 5-10mg SC daily for 10-20 days, repeated once or twice per year. Epithalon (AEDG tetrapeptide) activates telomerase (hTERT) in somatic cells and restores melatonin secretion from the aging pineal gland. Evening dosing aligns with pineal function and melatonin synthesis. In Khavinson studies, extended rodent lifespan by 13.3%. Russian clinical data spanning 15+ years supports safety. No Western clinical trials.
- Dose
- 1000mcg
- Frequency
- Once daily; continuous low-dose cycling (e.g., 3 months on, 1 month off)
- Timing
- Evening, 1-2 hours before bed
- Route
- subcutaneous
- Cycle
- 8-12 weeks
Alternative low-dose continuous protocol used by some longevity practitioners. 1-3mg/day SC on a cycling basis rather than the traditional high-dose pulse. Theoretical advantage: sustained low-level telomerase activation vs. periodic high pulses. Less studied than the standard Khavinson protocol. Often combined with Thymalin for synergistic immune + longevity effects (Khavinson's combination protocol reduced mortality 4.1x in elderly patients over 6 years).
Contraindications & Cautions
- hard stop — PregnancyNo human safety data during pregnancy. Telomerase-activating peptide could affect fetal cellular biology in unpredictable ways.Action: Do not use during pregnancy.
- hard stop — BreastfeedingNo data on excretion in breast milk. Safety not established.Action: Do not use while breastfeeding.
- hard stop — Under 18 years of ageResearch peptide. Not for pediatric use.Action: Do not provide to individuals under 18.
- caution — Active cancerEpithalon activates telomerase, which maintains telomere length and extends cellular replicative capacity. While this is beneficial for healthy cells, cancer cells commonly reactivate telomerase to achieve immortality. Exogenous telomerase activation could theoretically support tumor cell survival and proliferation, though direct evidence for this with epithalon is lacking.Action: Avoid in patients with active cancer. The theoretical risk of supporting tumor cell immortality warrants caution. Consult oncologist.
- caution — General useLimited human clinical trial data. Russian bioregulator peptide with primarily animal and small-scale human studies. Long-term effects of telomerase activation not fully characterized.Action: Use with awareness of limited evidence base. Monitor for unexpected effects.
Evidence
- emerging
Peptide promotes overcoming of the division limit in human somatic cells
Khavinson V, Bondarev IE, Butyugov AA (2003) — Bulletin of Experimental Biology and Medicine — PMID: 12937682
Epithalon (Ala-Glu-Asp-Gly) induced telomerase activity in human fetal fibroblast cultures that had reached their Hayflick limit, enabling additional cell divisions beyond the replicative senescence threshold. The peptide activated the catalytic subunit of telomerase (hTERT) and elongated telomeres. Suggests potential geroprotective mechanism through telomere maintenance.
- emerging
Peptide regulation of ageing
Khavinson V (2002) — Bulletin of Experimental Biology and Medicine
Khavinson summarized decades of work on short peptide bioregulators including epithalon (epitalon), showing effects on lifespan extension in animal models, melatonin normalization, and immune function restoration in aged organisms. Epithalon administration in elderly primates restored melatonin secretion patterns. Human observational data suggested reduced mortality in elderly patients receiving peptide bioregulators.
Stacks featuring this peptide
Based on Khavinson's landmark longevity studies where Epithalon + Thymalin reduced mortality by 4.1x in elderly patients over 6 years. Epithalon (AEDG tetrapeptide) activates telomerase, extending cellular replicative capacity and restoring pineal melatonin production. Thymalin restores thymic immune function — immune decline (immunosenescence) is a primary driver of age-related disease and infection mortality. SS-31 (Elamipretide) targets mitochondrial dysfunction, the third hallmark — it localizes to the inner mitochondrial membrane, stabilizing cardiolipin and restoring electron transport chain efficiency. NAD+ replenishes the cellular energy currency that declines ~50% from age 40-60, required by sirtuins, PARPs, and CD38 for DNA repair and epigenetic maintenance. Four hallmarks of aging addressed: telomere shortening, immunosenescence, mitochondrial dysfunction, and NAD+ depletion.
Epithalon (telomerase activation) + GHK-Cu (gene expression reset to youthful patterns) + Humanin (mitochondrial protection) + Thymalin (immune rejuvenation) + NAD+ (cellular energy restoration). Each targets a different hallmark of aging: telomere shortening, altered gene expression, mitochondrial dysfunction, immune decline, and NAD+ depletion.
For systemic skin rejuvenation beyond what topicals can achieve. GHK-Cu (copper peptide) resets skin gene expression — upregulating collagen I/III, elastin, decorin, and glycosaminoglycans while downregulating inflammatory and degradation genes. SC injection delivers GHK-Cu systemically rather than relying on limited topical penetration. BPC-157 promotes angiogenesis and tissue repair in the dermal layer. Epithalon activates telomerase in fibroblasts, potentially extending their replicative capacity (skin aging is driven partly by fibroblast senescence). Ipamorelin's nightly GH pulse stimulates skin thickness, hydration, and collagen synthesis — GH's cosmetic effects are well-documented in GH deficiency replacement studies.
DSIP (promotes delta-wave sleep architecture) + Ipamorelin (GH pulse during sleep, deepest sleep = most GH) + Epithalon (normalizes melatonin/circadian rhythm via pineal gland). DSIP increases time in deep sleep, ipamorelin capitalizes on that for maximum GH release, and epithalon restores age-related melatonin decline.
Research Summary
TIER 1 (Gold Standard): No Western Phase III RCTs. Khavinson & Morozov, 2003 — 6-year human study (n=266 elderly, 60-80 years): combination of epithalon + thymalin reduced mortality by 2.2x and cardiovascular mortality by 4.1x vs. controls. This is a controlled clinical trial but not to Western standards (Russian registration trial). TIER 2 (Strong): Khavinson VK & Bondarev VP, 2003 — epithalon activates telomerase in human somatic cells (Bull Exp Biol Med, PMID: 14565663). Anisimov VN et al., 2003 — epithalon extends lifespan and reduces tumor incidence in mice (Biogerontology, PMID: 14501183). Khavinson VK, 2002 — Peptides and Aging (monograph, Neuroendocrinology Letters). Khavinson et al. — epithalon restores melatonin in aged monkeys (multiple Russian journal publications). Khavinson peptide-DNA interaction studies (Bulletin of Experimental Biology and Medicine, multiple publications). TIER 3 (Moderate): Russian post-marketing data spanning 15+ years. Khavinson Institute clinical series documenting effects in hundreds of elderly patients. Practitioner case series from European and American anti-aging clinics. Conference presentations at A4M (American Academy of Anti-Aging Medicine), ESAAM, and World Congress on Anti-Aging Medicine. International pharmacopoeia — registered as geroprotector in Russia. Biohacking community telomere tracking data (informal, Tier 4). KEY FINDINGS: (1) Telomerase activation in human somatic cells is demonstrated in vitro. (2) Lifespan extension in animal models is consistent. (3) The 6-year human study is the strongest evidence but lacks Western replication. (4) Safety profile is excellent across all available data. (5) Melatonin restoration is a significant secondary benefit. GAPS: No Western RCTs. Independent replication of telomerase activation claims. Optimal dosing (the 10mg/day protocol is empirical, not dose-optimized in trials). Long-term effects of periodic telomerase activation. Whether oral/sublingual delivery is effective. ACTIVE TRIALS: No registered trials on ClinicalTrials.gov as of 2026.